Scholarlink

<p>Localized cutaneous leishmaniasis (LCL) is the most prevalent form of leishmaniasis, with infection control primarily dependent on cell-mediated immunity. Lesion healing results from a complex interplay among immune cells and soluble mediators. Using Luminex technology, we evaluated circulating and lesion microenvironment immune mediators, including chemokines, cytokines, and growth factors, in patients with LCL and nonspecific dermatitis. A robust proinflammatory response was observed in the lesion microenvironment of LCL patients, characterized by elevated levels of growth factors, important immune mediators potentially involved in tissue repair. Predictive modeling identified FGF, G-CSF, GM-CSF, IL-2, and IL-9 as key immune mediators distinguishing LCL from nonspecific dermatitis. Our results reveal that LCL presents a distinct soluble immune mediator signature from nonspecific dermatitis, exhibiting a set of biomarkers that not only define its immune mediator signature but also signal a possible role in the tissue repair process. Furthermore, we characterized the profile of soluble immune mediators of LCL patients, categorized according to the time evolution lesion. Our analysis revealed a predominance of biomarkers within the lesion microenvironment in patients with recent lesions (&lt; 2 months of evolution). On the other hand, in late lesions patients (&gt; 2 months of evolution), our data showed a predominance of biomarkers in the systemic circulation. Collectively, these findings provide novel insights into the immunopathogenesis of LCL and highlight candidate immune mediators for targeted prognostic evaluation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune Mediator Profile in the Inflammatory Microenvironment Reveals Potential Biomarkers of Wound Healing in Localized Cutaneous Leishmaniasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月28日

查看全文
  • Jaqueline Paulino de Souza,
  • Célia Maria Ferreira-Gontijo,
  • Francislane Ramalho Varella Pereira,
  • Marcela Tavares Caldas Eller,
  • Matheus Figueiredo Garrocho Ottoni-Vieira,
  • Julia Pereira-Martins,
  • Maryana Prates Rodrigues,
  • Joaquim Pedro Brito-de-Sousa,
  • Ariane Soares Nascimento,
  • Maria Nilza Pereira de Brito,
  • Bruno Oliveira Souza e Silva,
  • Thadeu Ramalho da Silva,
  • Maria Clara Coutinho Miranda de Figueiredo,
  • Érika Michalsky Monteiro,
  • Olindo Assis Martins-Filho,
  • Jordana Grazziela Alves Coelho-dos-Reis,
  • Marcelo Antônio Pascoal-Xavier,
  • Agnes Antônia Sampaio-Pereira,
  • Andréa Teixeira-Carvalho,
  • Vitor Hugo Simões Miranda,
  • Vanessa Peruhype-Magalhães

摘要

Localized cutaneous leishmaniasis (LCL) is the most prevalent form of leishmaniasis, with infection control primarily dependent on cell-mediated immunity. Lesion healing results from a complex interplay among immune cells and soluble mediators. Using Luminex technology, we evaluated circulating and lesion microenvironment immune mediators, including chemokines, cytokines, and growth factors, in patients with LCL and nonspecific dermatitis. A robust proinflammatory response was observed in the lesion microenvironment of LCL patients, characterized by elevated levels of growth factors, important immune mediators potentially involved in tissue repair. Predictive modeling identified FGF, G-CSF, GM-CSF, IL-2, and IL-9 as key immune mediators distinguishing LCL from nonspecific dermatitis. Our results reveal that LCL presents a distinct soluble immune mediator signature from nonspecific dermatitis, exhibiting a set of biomarkers that not only define its immune mediator signature but also signal a possible role in the tissue repair process. Furthermore, we characterized the profile of soluble immune mediators of LCL patients, categorized according to the time evolution lesion. Our analysis revealed a predominance of biomarkers within the lesion microenvironment in patients with recent lesions (< 2 months of evolution). On the other hand, in late lesions patients (> 2 months of evolution), our data showed a predominance of biomarkers in the systemic circulation. Collectively, these findings provide novel insights into the immunopathogenesis of LCL and highlight candidate immune mediators for targeted prognostic evaluation.